Fiocruz establishes partnership with Chinese scientific institutions

5 March 2018
brazil-big

Brazil’s prestigious Oswaldo Cruz Foundation (Fiocruz) has signed a Memorandum of Understanding with Shenzhen Third People's Hospital, Beijing Genomic Institute (BGI), Laboratory of Pathogenic Microbiology of the Institute of Immunological Microbiology of the Chinese Academy of Sciences (CAS), and the telecommunications company ZTE, in Shenzen, China.

The document establishes the foundations for a scientific cooperation agreement that will allow the setting up of two Brazil-China Centers for Research and Prevention of Infectious Diseases, one in Brazil and one in China.

According to the agreement, the centers will address basic and translational research applied to health, focusing on the prevention and control of epidemics such as influenza viruses, chikungunya, zika, dengue, yellow fever and oropouche fever, as well as other infectious diseases such as tuberculosis. The document represents a follow up the MoU signed between the Foundation and Chinese Center for Disease Control and Prevention (China CDC) in November, in São Paulo, Brazil.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical